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Abstract
Patients with chronic obstructive pulmonary disease (COPD) who are defined as frequent exacerbators suffer with 2 or more
exacerbations every year. The molecular mechanisms responsible for this phenotype are poorly understood. We
investigated gene expression profile patterns associated with frequent exacerbations in sputum and blood cells in a well-
characterised cohort. Samples from subjects from the ECLIPSE COPD cohort were used; sputum and blood samples from
138 subjects were used for microarray gene expression analysis, while blood samples from 438 subjects were used for
polymerase chain reaction (PCR) testing. Using microarray, 150 genes were differentially expressed in blood (.61.5 fold
change, p#0.01) between frequent compared to non-exacerbators. In sputum cells, only 6 genes were differentially
expressed. The differentially regulated genes in blood included downregulation of those involved in lymphocyte signalling
and upregulation of pro-apoptotic signalling genes. Multivariate analysis of the microarray data followed by confirmatory
PCR analysis identified 3 genes that predicted frequent exacerbations; B3GNT, LAF4 and ARHGEF10. The sensitivity and
specificity of these 3 genes to predict the frequent exacerbator phenotype was 88% and 33% respectively. There are
alterations in systemic immune function associated with frequent exacerbations; down-regulation of lymphocyte function
and a shift towards pro-apoptosis mechanisms are apparent in patients with frequent exacerbations.
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Introduction
Exacerbations of COPD are defined as an acute worsening of
symptoms beyond the daily variability seen in patients with COPD
and are associated with increased airway and systemic inflamma-
tion [1]. Exacerbations are commonly triggered by viruses or
bacteria, although other environmental trigger factors such as air
pollution are recognised [1,2]. The ECLIPSE study has recently
identified a frequent exacerbation phenotype present across all
GOLD airflow limitation stages, characterized by developing at
least 2 exacerbations every year over a 3 year follow up [3]. In the
same study there were subjects at all GOLD stages who did not
exacerbate at all over three years. Patients with more frequent
exacerbations are known to have worse quality of life and
increased mortality [4,5].
The cellular and molecular mechanisms responsible for the
increased susceptibility to exacerbations in the frequent exacerba-
tion phenotype are poorly understood. If the cascade of
inflammatory events that result in the clinical development of an
exacerbation episode is centred in the lungs, it is likely that there
are differences in the airway cells of patients with the frequent
exacerbation phenotype compared with those that do not have
exacerbations. However, if the cascade represents a generalized
systemic response to pathogens or other trigger factors, it is likely
that there will be differences that could be detected in immune
cells in the systemic circulation.
We hypothesized that there are differences in the gene
expression profile in the blood and airway cells of frequent
exacerbators compared with non-exacerbators. To test this
hypothesis we studied well characterized COPD subjects in the
ECLIPSE cohort. We investigated the gene expression profile
pattern associated with the frequent exacerbation phenotype in
sputum and blood cells.
Methods
Subjects
ECLIPSE is a 3-year multicentre longitudinal study to identify
novel endpoints in COPD; the methodology has been previously
described [6]. Sputum induction was performed and blood
samples obtained in a subset of 148 COPD ex-smokers at 14
sites at the start of the study. Samples of sufficient quality for gene
array analysis were obtained from 138 of these subjects. These
subjects were subsequently followed up for 3 years, and the
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e107381number of exacerbations was quantified. Blood samples obtained
from a different group of 215 COPD patients participating in
ECLIPSE were used for PCR analysis.
Ethics statement
ECLIPSE was ethically approved by the local ethics committee
at each participating centre; Clinicaltrials.gov identifier
NCT00292552; GSK Study Identifier SCO104960. All partici-
pants provided written informed consent.
Sputum induction and processing
The methods for sputum induction and processing have been
previously described [7] and are included in the supporting
information (File S1).
Whole blood collection
Using standard venipuncture techniques, 2.5 mls of blood was
drawn into each of two PAXGene blood collection tubes. The
isolation of RNA from these samples is described in the supporting
information (File S1).
Microarray processing
The performance of microarrays is described in the supporting
information (File S1).
Real time PCR
RNA was isolated and processed by Aros Applied Biotechnol-
ogy (Denmark) as described in the supporting information (File
S1).
Statistical analysis
Patients with frequent exacerbations were defined as those who
had experienced two or more exacerbations requiring oral
corticosteroids and/or antibiotics or were hospitalised within a
year, for each of the 3 years of the study as previously defined in
the ECIPSE study [3]. This group was compared to patients with
no exacerbations during this time period. Univariate analysis used
a p value of ,0.01 to define significant differences between
groups, and gene expression fold change (FC) levels as indicated in
the text. Individual genes were mapped to Genego pathways
(GeneGo, St. Joseph, MI, http://www.genego.com/metacore.
php), with p#0.01 and FDR,0.05 used to identify significant
pathways. The gene array data is accessible at geo@ncbi.nlm.nih.
gov (GEO ID GSE4837 and GSE22148).
A linear model analysis of variance was also used to identify a
set of genes associated with the frequent exacerbator phenotype;
The analysis was adjusted for age, gender and batch by including
these variables as terms in the model. Previous subject reported
exacerbation history was also used as one of the variables in the
model. The history of exacerbations after one year was used to
create the model, as there were more subjects with either frequent
or zero exacerbations after one year (44 versus 62 respectively)
compared to three years (17 vs 29 respectively). The subjects were
randomly split into a training set and a validating set using the
data at year 1 as shown in Fig. 1. The training set included 29
subjects with frequent exacerbations and 41 with zero exacerba-
tions and for the validating set these numbers were 15 and 21
respectively. 100 training sets were used to create 100 predictive
models. Stepwise logistic regression was used to select the most
significant predictors; The model structure was (ln[p/(1-p)]= a+
b1(predictor1) + b2(predictor2)…. + e), p is the probability that the
subject will have 2 or more exacerbations and p/(1-p) is the ‘‘odds
ratio’’ and ln[p/(1-p)] is the log odds ratio, or ‘‘logit’’. Each model
was checked against the 1000 validating sets to determine its
prediction accuracy. One of the best performing models was then
checked against the whole sample set of 44 frequent exacerbators
compared to 62 zero exacerbators.
Real time PCR data were similarly analyzed using a linear
model analysis of variance. A covariate was also included to
account for any change in expression due to the RNA loading of
the samples. This covariate was represented by the scores from the
first principal component obtained from a PCA analysis of the two
housekeeper genes.
Results
Microarray data
The demographic and clinical characteristics at baseline for the
138 COPD patients whose sputum and blood samples were used
for gene arrays are shown in the supporting information (Table S1
in File S1). After 3 years of follow up, there were 117 patients who
completed the study with a documented exacerbation history; the
demographic details of these subjects are shown in Table 1; 17
patients were frequent exacerbators and 29 patients had zero
exacerbations.
There were no differences between groups in the blood counts
(p.0.05 for all comparisons between groups). A total of 150 genes
(166 probesets) were differentially expressed in blood at the level
of.61.5 FC (p#0.01) between frequent compared to zero
exacerbators. In contrast, in the sputum cells, there were only 6
genes (9 probesets) differentially expressed between these groups.
The most highly regulated genes in blood and sputum cells are
shown in Table 2, with a full list of genes differentially expressed.
61.5 FC in the supporting information (Table S2 in File S1).
The intermediate group of patients (n=71) who had exacerba-
tions but did not meet the criteria for inclusion in the frequent
exacerbation group had only 21 genes differentially regulated in
blood compared to zero exacerbators; there was a greater
separation of gene expression in the frequent exacerbation group
Figure 1. Identification of a set of genes in blood associated
with the frequent exacerbator phenotype; multivariate analy-
sis using micro-array data 1 year follow up data (n=106),
followed by univariate analysis of 3 year follow up data (n=46)
and univariate analysis of a different population (n=215) by
PCR. FE= frequent exacerbators; ZE = zero exacerbators.
doi:10.1371/journal.pone.0107381.g001
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tially expressed in blood from the intermediate group compared to
zero exacerbators (21 genes) and compared to frequent exacer-
bators (20 genes) are shown in the supporting information (Tables
S3 and S4 in File S1). Fig. 2 shows that from the 21 genes
differentially expressed in intermediate group compared to zero
exacerbators, 4 were also differentially expressed in the frequent
exacerbators compared to zero exacerbators (listed in supporting
information).
Pathway analysis
As there were relatively fewer gene expression changes observed
in the sputum cells of frequent exacerbators compared to zero
exacerbators, the rest of the analysis focused on whole blood gene
expression. Genego pathway analysis was performed on 811 genes
Table 1. Demographics of the COPD subjects for microarray analysis.
All Zero Intermediate Frequent
N 117 29 71 17
GOLD Stage II (%) 51 55 55 29
GOLD Stage III (%) 41 38 39 53
GOLD Stage IV (%) 8 7 6 18
Male (%) 66 69 65 65
Mean age 64.9 63.2 65.7 64.8
Mean pack years 46.8 52.0 45.3 43.7
Percent Predicted FEV1 (%) 50.3 51.8 51.7 42.3
LABA (%) 78.6 58.6 83.1 94.1
Inhaled corticosteroid (%) 75.2 55.2 80.3 88.2
Blood WBC 7.5 7.5 7.3 8.2
Blood neutrophil count 4.9 4.8 4.8 5.5
Blood eosinophil count 0.24 0.21 0.24 0.27
Blood leukocyte count 1.87 2.05 1.82 1.80
Blood monocyte count 0.46 0.43 0.44 0.59
Exacerbations were defined over a 3 year follow up; frequent denotes 2 or more exacerbations each year, zero denotes no exacerbations in any year, and intermediate
denotes patients who did not fit the frequent or zero exacerbation phenotype. Blood counts are mean values (X10
9 cells/L).
doi:10.1371/journal.pone.0107381.t001
Table 2. The 10 most highly regulated genes in sputum and blood from microarray analysis; a positive fold change = increase in
frequent exacerbators compared to zero exacerbators, a negative fold change = decrease in frequent exacerbators compared to
zero exacerbators.
Gene Name Affy. ID Fold change p value Sample
LOC284723 232245_at 1.71 0.009 Sputum
ANKRD28 213035_at 1.71 0.008 Sputum
LOC284723 1559977_a_at 1.65 0.009 Sputum
LDHAL6B 210712_at 1.55 0.001 Sputum
MIA 206560_s_at 1.53 0.008 Sputum
OASL 205660_at 21.54 0.009 Sputum
RHCE 215819_s_at 2.25 0.010 Blood
CCNA1 205899_at 2.23 0.009 Blood
ITGB2 236988_x_at 2.21 0.008 Blood
COL4A3 222073_at 22.05 0.001 Blood
FCRL1 235982_at 22.06 ,0.001 Blood
FCRL2 221239_s_at 22.06 ,0.001 Blood
CD200 209583_s_at 22.09 0.002 Blood
HLA-DQB1 212999_x_at 22.22 0.009 Blood
TCL6 219840_s_at 22.59 ,0.001 Blood
HLA-DQA1 236203_at 23.27 0.003 Blood
Affy. ID = affymatrix identification number. There was no overlap between sputum and blood for highly expressed genes.
doi:10.1371/journal.pone.0107381.t002
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There were 35 significant pathways (p#0.01, FDR,0.05) where
at least 4 genes were regulated, including 14 apoptosis pathways, 8
immune response pathways and 5 cell development pathways;
these pathways are shown in the supporting information (Table S5
in File S1). The 5 most highly regulated pathways are shown in
Table 3, and included 2 apoptosis signalling pathways (ceramide
and lymphotoxin beta receptor [LTBR] signalling) and 3
lymphocyte signalling pathways (inducible T-cell costimulator
[ICOS] and CD28 signalling in T cells, and B cell receptor
signalling).
Within the apoptosis pathways, the well recognised pro-
apoptotic genes BAD, BAX and LTBR had increased expression,
while the anti-apoptotic gene BCL2 had decreased expression,
indicating a shift towards pro-apoptotic signalling. Within the
lymphocyte signalling pathways, there was decreased expression of
genes involved in T cell activation such as the co-stimulatory
molecules CD28 and ICOS, the transcription factors NFATC2
and AKT3 and HLA genes that encode MHC proteins
responsible for antigen presentation to T cells. B cell activation
genes also showed decreased expression, including CD19,
complement receptor 2 (CR2) and B-cell linker protein (BLNK),
although the B cell regulatory protein CD22 had increased
expression. There was also decreased expression of other proteins
involved in B cell function such as the FC like receptor (FCLR)
family members FCLR1, 2 and 5.
Multivariate analysis
Multivariate analysis of the gene array data was performed to
identify a set of genes most closely associated with the frequent
exacerbator phenotype. The 17 and 29 patients followed over
three years was an insufficient sample size to create a training and
validation set. As described in the methods and Fig. 1, the clinical
history of exacerbations after 1 year was used to create the training
and validation set, as there were more subjects who experienced
no exacerbations and frequent exacerbations in this time period
(62 and 44 respectively). Multivariate analysis was performed using
368 genes with FC.61.2, p#0.01 between these groups. The
best performing model included these 6 genes; SYT6, ARH-
GEF10, PHPT1, MGC31963, LAF4 and B3GNT (Table 4).
The expression of these 6 genes between frequent and zero
exacerbators using 3 year follow up clinical history is shown in
Table 4; ARHGEF10, PHPT1, MGC31963, LAF4 and B3GNT
were significantly differentially expressed between groups, but not
SYT6.
PCR analysis
PCR analysis of the 5 genes shown by microarray to be
differentially expressed in frequent and zero exacerbators after 3
years (ARHGEF10, PHPT1, MGC31963, LAF4 and B3GNT)
was performed in a different group of 215 subjects (see Table 5 for
demographic details), including 75 with zero exacerbations and
140 with frequent exacerbations in the 3 year follow up period.
PLCL2 and FCL5, which were also differentially expressed on
microarray, and SYT6 were also analysed by PCR.
B3GNT1, LAF4, ARHGEF10 and PLCL2 expression were
significantly different between frequent and zero exacerbators (see
Table 4). SYT6, MGC31963 and FCL5 did not achieve statistical
significance, while PHPT1 had a complete reversal of signal.
B3GNT, LAF4 and ARHGEF10 were retested as a model in this
population; these 3 genes predicted the frequent exacerbation
phenotype with sensitivity and specificity of 88% and 33%
respectively, with the values improving to 91% and 81%
respectively when the exacerbation history in the previous year
was considered. Modelling previous exacerbation history alone
gave sensitivity and specificity of 90% and 83% respectively.
Discussion
This study has demonstrated differences in the gene expression
profile of COPD patients with frequent exacerbations compared
to those with no exacerbations over a 3 year period in ECLIPSE.
There were 150 genes differentially expressed in the circulating
cells of the two groups, with only 6 differentially regulated genes in
sputum cells. This suggests alterations in systemic immune
function that contribute to the frequent exacerbation phenotype
rather than a specific pulmonary immune defect.
Our results suggest that future investigations into the patho-
physiology of COPD exacerbations should focus on changes that
occur in the systemic immune system. We have not proved
mechanistically that the changes observed here are the cause or
consequence of frequent exacerbations, but nevertheless provide a
starting point for further investigations into the gene expression
differences observed. Microarray gene expression profiling is often
‘‘hypothesis generating’’, and our results have generated a number
of hypotheses regarding potentially dysregulated immunological
pathways in COPD frequent exacerbators. We have provided a
degree of validation of our findings by performing PCR analysis in
a different group of COPD patients. The microarray gene
expression findings reported here serve as a basis for future
investigations of potential mechanisms involved in COPD
exacerbations.
A subset of the microarray gene expression findings were
investigated in a different, and larger, group of patients by PCR.
Four out of seven microarray genes that showed significant
differences in blood using the 3 year follow up data were also
significantly different in the PCR analysis in a separate population.
Microarray gene expression analysis often produces false positive
results due to multiple testing, so it is desirable to validate the
findings using different techniques and/or a different sampling
population. A major strength of this study is the use of two cohorts
for replication. The PCR analysis indicates that many of the
micro-array results are not false positive findings. Our pathway
analysis describes a large number of genes involved in lymphocyte
signalling and apoptosis pathways, and the presence of some false
positive data would not change these overall findings.
Figure 2. Venn diagram showing the number of differentially
regulated genes in blood (fold change +/21.5 and p,0.01)
between frequent exacerbators (F), the intermediate group (I),
and zero exacerbators (Z); for example, F vs I denotes number
of differentially regulated genes between frequent exacer-
bators and the intermediate group.
doi:10.1371/journal.pone.0107381.g002
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using the same sputum samples from the subjects in this study, we
have recently shown a large set of genes associated with disease
severity defined by FEV1 or the degree of emphysema at the FC
level of 2 [7]; 277 genes were differentially regulated in severe
compared to moderate COPD, and 198 genes were differentially
regulated according to the degree of emphysema respectively. In
stark contrast, there were no induced sputum genes regulated at
this FC level in frequent exacerbators compared to zero
exacerbators. Furthermore, the gene expression differences in
whole blood were not due to differences in the composition of the
leukocytes, as the differential white cell counts were similar in
patients with frequent exacerbations compared to those with zero
exacerbations.
Exacerbations are often caused by respiratory pathogens, such
as viruses and bacteria [1,2]. It is thought that an exaggerated
and/or prolonged immune response to pathogens in susceptible
COPD patients leads to an acute exacerbation. One might
reasonably assume that patients with frequent exacerbations would
have changes within the pulmonary immune system that pre-
dispose to an exaggerated immune response after exposure to a
respiratory pathogen. Alternatively, the abnormality could be
systemic in nature. Our results suggest dysregulation of systemic
immune function in COPD frequent exacerbators rather than
dysfunction limited to the lungs.
Systemic immunological response
There was decreased expression of the T-cell receptor co-
stimulatory molecules CD28 and ICOS, and GeneGo analysis
identified multiple changes within these signalling pathways. Co-
stimulatory signals through CD28 and ICOS enhance T cell
activation following T-cell receptor stimulation [8]. The expres-
sion of HLA genes that encode MHC class II was also reduced,
suggesting a diminished capacity for antigen presentation to T cells
[9]. Reduced antigen presentation coupled with reduced co-
stimulation indicates a decreased adaptive immune response in
frequent exacerbators. Furthermore, there was also decreased
expression of T cell transcription factors such as NFATC2 in
frequent exacerbators; this transcription factor is involved in T cell
cytokine production [8,10], and reduced gene expression levels
may be a downstream consequence of decreased T cell receptor
signalling. There were other T cell specific genes that were highly
regulated (Table 2), including decreased expression of. 2 FC for
CD200 which is known to suppress inflammatory lymphocyte
responses [11] and TCL-6 [12] which is expressed in T cell
leukaemia cells. The altered expression of so many genes involved
in T cell signalling strongly suggests that altered T cell function
plays a mechanistic role in the frequent exacerbator phenotype.
There was decreased expression of B cell activation genes
including the co-receptors CD19 and CR2, and the downstream
signalling molecule BLNK [13,14]. CR2, also known as CD21,
binds to complement attached to immune complexes; CR2
expression is decreased in auto-immune diseases [15], which
may represent physiological down-regulation rather than the
primary cause of auto-immunity. In the context of COPD
exacerbations, it is also possible that reduced B cell signalling is
a primary physiological mechanism that causes susceptibility to
exacerbations, or a physiological response to repeated or
prolonged infection. The expression of the B cell regulatory
protein CD22 [16] was increased in frequent exacerbators, again
compatible with negative regulation of B cell function.
There is evidence of impaired T-cell receptor signalling in
autoimmune diseases [17,18]. Similarly, it has recently been
shown that the expression of T-cell receptor signalling components
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findings now suggest that peripheral blood T and B cells are in a
state of decreased activation in COPD patients with frequent
exacerbations. This may reduce their ability to act effectively
during infections, thus leading to an increased susceptibility to
exacerbations.
Pulmonary lymphoid follicles numbers are increased in COPD
patients [20]; These organised structures facilitate antigen
presentation, cytokine secretion and antibody production by B
cells. The exact nature of the antigen presentation is unknown,
and may be self-antigens or pathogen derived antigens. It would
be interesting to know if there is also reduced activation of cells
within lymphoid follicles of COPD exacerbators.
Cell death and tissue repair
Apoptosis is the process of programmed cell death that occurs as
part of normal tissue homeostasis. We observed a shift towards
pro-apoptotic mechanisms in peripheral blood samples of frequent
exacerbators, as the expression of the pro-apoptotic genes BAD
[21], BAX [21] and LTBR [22] was increased, while anti-
apoptotic BCL2 [21] expression was decreased. This suggests that
immune cells in the peripheral circulation of frequent exacerbators
have an increased rate of apoptosis. There is evidence of increased
apoptosis in the lungs of COPD patients [23], which may be
related to increased levels of oxidative stress. A balance of
increased tissue apoptosis with reduced clearance by immune cells
can lead to increased tissue inflammation. Immune cells cannot
participate in the normal immune response while undergoing
programmed cell death; this may be an important mechanism
contributing to a reduced immune response against pathogens in
frequent exacerbators.
Other pathway genes
Table 2 shows some relatively highly regulated genes that may
be of biological relevance in COPD. For example, CCNA1
encodes the protein cyclin A1 which is involved in cell cycle
processes [24] and was increased in frequent exacerbators.
Increased CCNA1 may indicate increased cell cycle in blood cells
capable of cell division, such as lymphocytes. There was also
increased ITGB2 expression; this gene encodes CD18 which is
involved in leukocyte adhesion [25].
The 3 gene panel confirmed by PCR were B3GNT1 which
encodes beta-1,3-N-acetylglucosaminyltransferase enzyme in-
volved in poly-N-acetyllactosamine synthesis [26], LAF4 which is
a transcription factor involved in lymphoid development [27], and
ARHGEF10 which is a rho GTPase involved in cell signalling
events [28]. The expression of these genes was reduced in frequent
exacerbators. Reduced LAF4 expression is compatible with our
other findings of decreased lymphocyte signalling in frequent
exacerbators. It is unclear if our findings regarding B3GNT1 and
ARHGEF10 are indicative of mechanisms involved in frequent
exacerbations, or biomarkers of patients who have such events.
Further studies of the function of these genes, and the other
significantly regulated genes reported here, in COPD patients
would shed light on their potential biological roles. It would also be
of value to study the protein expression levels of these genes to
provide further validation of our findings.
Table 4. Gene expression changes in the 6 gene panel identified by microarray analysis using the phenotype data after 1 year.
Microarray; 1 year phenotype Microarray; 3 year phenotype PCR; 3 year phenotype
Fold Change P Value Fold Change P Value Fold Change P Value
B3GNT1 21.4 ,0.0001 21.5 ,0.0001 21.2 ,0.0001
SYT6 1.4 ,0.0001 1 0.881 1 0.693
LAF4 21.5 ,0.0001 21.7 0.0007 21.4 ,0.0001
ARHGEF10 21.4 0.013 21.3 0.0439 21.4 ,0.0001
MGC31963 1.4 0.0001 1.6 0.00046 1 0.5601
PHPT1 1.2 0.003 1.4 0.007 21.3 ,0.0001
FCL5 21.5 0.01 21.83 0.003 21.16 0.131
PLCL2 21.3 0.002 21.43 0.006 21.65 0.0008
The gene expression changes using the phenotype data after 3 years from the microarray population and PCR population are shown. Positive fold change = increase in
frequent exacerbators compared to zero exacerbators, negative fold change = decrease in frequent exacerbators compared to zero exacerbators.
doi:10.1371/journal.pone.0107381.t004
Table 5. Demographics of the COPD subjects for PCR
analysis.
None Frequent
N7 5 1 4 0
Stage II (%) 44 30
Stage III (%) 31 42
Stage IV (%) 25 28
Male (%) 65 56
Mean age 63 63
Mean pack Years 56 48
Percent predicted FEV1 (%) 48 42
Current smokers (%) 38.6 37.6
LABA (%) 45 89
Inhaled corticosteroid (%) 51 94
Blood WBC 7.7 8.2
Blood neutrophil count 5 5.4
Blood eosinophil count 0.24 0.26
Blood leukocyte count 0.44 0.52
Blood monocyte count 2.02 1.95
Exacerbations were defined over a 3 year follow up; frequent denotes 2 or more
exacerbations each year, zero denotes no exacerbations in any year, and
intermediate denotes patients who did not fit the frequent or zero exacerbation
phenotype. Blood counts are mean values (X10
9 cells/L).
doi:10.1371/journal.pone.0107381.t005
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There are other studies that have investigated gene expression
profiles in COPD peripheral blood using isolated cells [29,30].
The novelty of our work is that we have investigated gene
expression associated with exacerbation history; previous studies
have not addressed this question. The interpretation of these
previous studies is often restricted by relatively small sample sizes.
However, a recent large study (n=211) investigated gene
expression associated with the presence and severity of COPD
[30]. Interestingly, there were some findings in common with our
study; T cell receptor signalling was found to be altered, with
PLCL2, which is involved in signal transduction processes, being
one of the differentially regulated genes [31].
Multivariate analysis
Multivariate modelling identified 3 genes in blood samples that
could be used with high sensitivity (91%) to predict the frequent
exacerbator phenotype. The sensitivity of this 3 gene panel was as
good as the clinical history (90%). A previous history of
exacerbations is a good predictor of future exacerbations [5],
and our results confirm that clinical history is reliable and sensitive
in this regard. We do not suggest this gene panel could replace the
clinical history. However, there are situations where this gene
panel may be useful, such as confirmation of the history in clinical
practice when deciding whether to start a patient on a therapy
targeted against exacerbations, or in clinical trials to objectively
confirm the frequent exacerbator phenotype.
Strengths of the study
This study had several strengths. First, it included a derivative
and a validating cohort of very well characterized patients followed
prospectively using the same procedure for data gathering and
analyses. Second, the simultaneous measurement of gene expres-
sion in two anatomical compartments (sputum and blood) provides
information about the potential contribution of local versus
systemic changes in the genesis of COPD exacerbations. Our
data suggests that it is important to not only study the lungs, but
also the systemic compartment when attempting to explain the
pathogenesis of exacerbations. The differentially regulated genes
reported here in the blood can be further investigated to
understand the altered immunobiology in COPD frequent
exacerbators.
Limitations of the study
There are several potential limitations. First, the timing of
sample collection in relation to exacerbations. We were extremely
careful to collect samples from patients during the stable state, at
least 4 weeks after an exacerbation, to avoid gene expression
changes that were due to episodes of exacerbation themselves. The
lack of induced sputum signals indicates that we were successful in
this regard. Secondly, it could be argued that therapy, most
notably inhaled corticosteroids, could have influenced the gene
expression. More COPD subjects were taking inhaled corticoste-
roids in the frequent exacerbator phenotype (88.2% - see Table 1),
likely because treatment guidelines suggest that these drugs should
be prescribed to such patients. Whole blood gene expression in the
intermediate group who had similar inhaled corticosteroid usage
(80.3%) compared with the frequent exacerbators, but had a lower
level of exacerbations, showed only 21 genes that were different
compared to zero exacerbators, which is lower than the
comparison of frequent exacerbators with zero exacerbators (150
genes). This demonstrates that any inhaled corticosteroid effect on
gene expression was low and did not account for the major
differences in gene expression. Thirdly, it could be argued that the
study has little clinical applicability. However, improved under-
standing of pathways associated with frequent exacerbations may
lead to the development of novel therapies targeting immune
defects in this subset of patients. Our results provide insights into a
number of pathways that provide the basis for future investiga-
tions.
It would be of interest to study the genes reported here
longitudinally to observe changes over time. It is probable that
gene expression patterns in COPD patients change over time, and
this may be associated with a change in clinical phenotype such as
frequency of exacerbations.
Conclusions
We have demonstrated changes in the systemic immune
function associated with the frequent exacerbator phenotype.
There was down-regulation of lymphocyte function and a shift
towards pro-apoptosis mechanisms in the peripheral blood of this
phenotype. These may be important mechanisms that are
responsible for the frequent exacerbation events observed in these
patients and potentially their modulation could lead to a decrease
in the number and/or duration of the episodes. More importantly,
this study shows that the frequent exacerbator phenotype may
have a biological underpinning and is not the product of simple
perception or type of health delivery bias.
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